BMY · Bristol-Myers Squibb Company
$62.09
+1.66% last session
End-of-day data · updated 2026-07-28
Market cap
$128B
Enterprise value
$164B
Trailing P/E
17.5
Forward P/E
10.1
Dividend yield
4.0%
Beta
0.24
Avg volume
12M
Employees
32K
2D change
—
5D change
1.71%
10D change
3.00%
30D change
9.99%
60D change
10.64%
MTD change
12.09%
YTD change
19.90%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BMY
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-10
Latest call per bank · past 12 months
Bank of America
Buy$66.00
+6.3% vs priceHSBC
Hold$60.00
-3.4% vs priceRBC Capital
Sector Perform$60.00
-3.4% vs priceBarclays
Overweight$75.00
+20.8% vs priceCitigroup
Neutral$64.00
+3.1% vs priceWells Fargo
Equal-Weight$60.00
-3.4% vs priceUBS
Buy$65.00
+4.7% vs priceMorgan Stanley
Underweight$37.00
-40.4% vs priceGoldman Sachs
Neutral$57.00
-8.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-10 | Bank of America | Maintains | Buy | $67.00 → $66.00 |
| 2026-07-06 | Cantor Fitzgerald | Reiterates | Neutral | $54.00 |
| 2026-04-09 | Bank of America | Maintains | Buy | $68.00 → $67.00 |
| 2026-04-08 | Guggenheim | Reiterates | Buy | $72.00 |
| 2026-04-08 | Cantor Fitzgerald | Maintains | Neutral | $45.00 → $54.00 |
| 2026-03-17 | HSBC | Maintains | Hold | $53.00 → $60.00 |
| 2026-02-25 | RBC Capital | Initiates | Sector Perform | $0.00 → $60.00 |
| 2026-02-23 | Piper Sandler | Maintains | Overweight | $66.00 → $75.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 69 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 11.0% above the 50-day MA ($57.30).
- Price vs 200-day MA: Trading 17.3% above the 200-day MA ($54.22).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is positive (+0.41) — short-term momentum is improving.
- 52-week range: Price is within 5% of the 52-week high ($63.60).
BMY Price Chart
Loading chart for BMY…
Fundamentals
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
More in Drug Manufacturers - General
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.